Stephen B Williams1, Marcus G K Cumberbatch2, Ashish M Kamat3, Ibrahim Jubber2, Preston S Kerr1, John S McGrath4, Hooman Djaladat5, Justin W Collins6, Vignesh T Packiam7, Gary D Steinberg8, Eugene Lee9, Wassim Kassouf10, Peter C Black11, Yannick Cerantola12, James W F Catto13, Siamak Daneshmand14. 1. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. 2. Academic Urology Unit, University of Sheffield, Sheffield, UK. 3. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Urology, Royal Devon and Exeter NHS Trust, Exeter, UK. 5. USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 6. Department of Urology, University College London Hospital, London, UK. 7. Department of Urology, Mayo Clinic, Rochester, MN, USA. 8. Department of Urology, New York University, New York, NY, USA. 9. Department of Urology, University of Kansas, Kansas City, KS, USA. 10. Department of Urology, McGill University Health Center, Montreal, QC, Canada. 11. Department of Urologic Science, University of British Columbia, Vancouver, BC, Canada. 12. Service d'urologie, CHU vaudois, Lausanne, Switzerland. 13. Academic Urology Unit, University of Sheffield, Sheffield, UK. Electronic address: j.catto@sheffield.ac.uk. 14. USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: daneshma@med.usc.edu.
Abstract
CONTEXT: Enhanced Recovery After Surgery (ERAS) is a perioperative approach to managing surgical patients. The impact of ERAS on radical cystectomy (RC) outcomes remains understudied. OBJECTIVE: To review the literature regarding ERAS protocols and RC outcomes. The primary outcome was hospital length of stay (LOS). EVIDENCE ACQUISITION: A systematic review of the articles published from 1970 through 2018 was conducted. Individual patient data (IPD) were requested and a meta-analysis was performed. EVIDENCE SYNTHESIS: A total of 4197 articles were retrieved and 22 (reporting 4048 patients) were selected for the review. LOS followed by 30-d and that followed by 90-d complications were the most common endpoints. ERAS use was associated with reduced morbidity, quicker bowel recovery, and shorter LOS, without affecting mortality. IPD were obtained for 2077 patients from 11 studies. In multivariable models, LOS was associated with ERAS use (regression coefficient: -4.54 [95% confidence interval {CI}: -5.79 to -3.28] d with ERAS p < 0.001) and Charlson Comorbidity Index (+1.64 [1.38-1.90] d for each point increase, p < 0.001), and varied between hospitals (from -1.59 [-3.03 to -0.14] to +4.55 [1.89-7.21] d, p < 0.03). Individual ERAS components associated with shorter LOS included no nasogastric (NG) tube (-8.70 [-11.9 to -5.53] d, p < 0.001) and local anesthesia blocks compared with regional anesthesia (-3.29 [-6.31 to -0.27] d, p = 0.03). CONCLUSIONS: ERAS protocols were associated with reduced LOS and postoperative complication rate. Avoidance of NG tubes and use of local anesthesia blocks were significantly associated with reduced LOS. These findings reflect different components of recovery, which ERAS can optimize and further support documentation of the use of ERAS components when reporting RC outcomes. PATIENT SUMMARY: Use of enhanced recovery in patients undergoing surgery to remove the bladder is associated with fewer surgical complications and a shorter hospital stay. Avoidance of nasogastric tubes and use of local anesthesia after the operation were associated with a shorter length of stay.
CONTEXT: Enhanced Recovery After Surgery (ERAS) is a perioperative approach to managing surgical patients. The impact of ERAS on radical cystectomy (RC) outcomes remains understudied. OBJECTIVE: To review the literature regarding ERAS protocols and RC outcomes. The primary outcome was hospital length of stay (LOS). EVIDENCE ACQUISITION: A systematic review of the articles published from 1970 through 2018 was conducted. Individual patient data (IPD) were requested and a meta-analysis was performed. EVIDENCE SYNTHESIS: A total of 4197 articles were retrieved and 22 (reporting 4048 patients) were selected for the review. LOS followed by 30-d and that followed by 90-d complications were the most common endpoints. ERAS use was associated with reduced morbidity, quicker bowel recovery, and shorter LOS, without affecting mortality. IPD were obtained for 2077 patients from 11 studies. In multivariable models, LOS was associated with ERAS use (regression coefficient: -4.54 [95% confidence interval {CI}: -5.79 to -3.28] d with ERAS p < 0.001) and Charlson Comorbidity Index (+1.64 [1.38-1.90] d for each point increase, p < 0.001), and varied between hospitals (from -1.59 [-3.03 to -0.14] to +4.55 [1.89-7.21] d, p < 0.03). Individual ERAS components associated with shorter LOS included no nasogastric (NG) tube (-8.70 [-11.9 to -5.53] d, p < 0.001) and local anesthesia blocks compared with regional anesthesia (-3.29 [-6.31 to -0.27] d, p = 0.03). CONCLUSIONS: ERAS protocols were associated with reduced LOS and postoperative complication rate. Avoidance of NG tubes and use of local anesthesia blocks were significantly associated with reduced LOS. These findings reflect different components of recovery, which ERAS can optimize and further support documentation of the use of ERAS components when reporting RC outcomes. PATIENT SUMMARY: Use of enhanced recovery in patients undergoing surgery to remove the bladder is associated with fewer surgical complications and a shorter hospital stay. Avoidance of nasogastric tubes and use of local anesthesia after the operation were associated with a shorter length of stay.
Authors: James W F Catto; Pramit Khetrapal; Federico Ricciardi; Gareth Ambler; Norman R Williams; Tarek Al-Hammouri; Muhammad Shamim Khan; Ramesh Thurairaja; Rajesh Nair; Andrew Feber; Simon Dixon; Senthil Nathan; Tim Briggs; Ashwin Sridhar; Imran Ahmad; Jaimin Bhatt; Philip Charlesworth; Christopher Blick; Marcus G Cumberbatch; Syed A Hussain; Sanjeev Kotwal; Anthony Koupparis; John McGrath; Aidan P Noon; Edward Rowe; Nikhil Vasdev; Vishwanath Hanchanale; Daryl Hagan; Chris Brew-Graves; John D Kelly Journal: JAMA Date: 2022-06-07 Impact factor: 157.335
Authors: Simone Albisinni; Marco Moschini; Ettore Di Trapani; Francesco Soria; Andrea Mari; Atiqullah Aziz; Jeremy Teoh; Ekaterina Laukhtina; Keiichiro Mori; David D'Andrea; Diego M Carrion; Wojciech Krajewski; Mohammad Abufaraj; Alessia Cimadamore; Wei Shen Tan; Ronan Flippot; Jonathan Khalifa; Kimberly Gonsette; Benjamin Pradere Journal: World J Urol Date: 2021-06-02 Impact factor: 4.226
Authors: Sophia Liff Maibom; Ulla Nordström Joensen; Alicia Martin Poulsen; Henrik Kehlet; Klaus Brasso; Martin Andreas Røder Journal: BMJ Open Date: 2021-04-14 Impact factor: 2.692
Authors: Thomas Ying; Pablo Borrelli; Lars Edenbrandt; Olof Enqvist; Reza Kaboteh; Elin Trägårdh; Johannes Ulén; Henrik Kjölhede Journal: Eur Radiol Exp Date: 2021-11-19
Authors: Wei Shen Tan; Jeffrey J Leow; Maya Marchese; Ashwin Sridhar; Giles Hellawell; Matthew Mossanen; Jeremy Y C Teoh; Sarah Fowler; Alexandra J Colquhoun; Jo Cresswell; James W F Catto; Quoc-Dien Trinh; John D Kelly Journal: Eur Urol Open Sci Date: 2021-09-20
Authors: Frederik König; Benjamin Pradere; Nico C Grossmann; Fahad Quhal; Pawel Rajwa; Ekaterina Laukhtina; Keiichiro Mori; Satoshi Katayama; Takafumi Yanagisawa; Hadi Mostafai; Reza Sari Motlagh; Abdulmajeed Aydh; Roland Dahlem; Shahrokh F Shariat; Michael Rink Journal: Transl Cancer Res Date: 2022-04 Impact factor: 1.241